INDEVUS REPORTS RESULTS OF PAGOCLONE STUDY
Indevus Pharmaceuticals has reported top-line results from the Phase II clinical trial for pagoclone in persistent developmental stuttering. Results from the trial showed that pagoclone produced a statistically significant benefit in multiple primary and secondary endpoints compared to placebo.
In addition, pagoclone produced either numerically superior improvement or trends for significant improvement on virtually all other primary and secondary endpoints when compared to placebo. Pagoclone was also shown to be well-tolerated and not associated with any serious adverse events.